PEDIATRICS Vol. 14 No. 4 October 1954, pp. 364
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by PETERMAN, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by PETERMAN, M. G.

NUVARONES® IN THE TREATMENT OF CONVULSIVE DISORDERS (CLINICAL NOTE)

M. G. PETERMAN M.D.

FOR the past six years a new hydantoinate, 3-methyl 5-phenylhydantoin. Nuvarone®, has been tried in selected cases of convulsive disorders. A preliminary report was made in 1952. This compound was being investigated simultaneously by others and two reports have appeared. The latter concerned 130 patients, 91 of whom were treated for one to 24 months. The results were reported as "good" in 44 and "fair" in 38 patients. The side effects were noted as "mild and transitory."

In the present series 72 patients under 16 years of age were treated for six months to six years. In nine patients Nuvarone® was the initial drug in treatment. In 38 patients Nuvarone® was gradually substituted for other compounds which had been inadequate. Nuvarone® was used in conjunction with other preparations such as phenobarbital or Gemonil® in 34 patients. It should not be used with other hydantoin compounds, Phenurone®, or the diones.

Complete blood counts, complete urinalyses (including urobilinogen tests), sedimentation rates, and electroencephalograms were done on all patients before and after Nuvarone® was started. The blood counts and urinalyses were repeated in two weeks and monthly thereafter with platelet counts in addition. Ieterus index and sedimentation rate were obtained every one to three months. No abnormal changes were noted. Two patients developed leucopenia but none developed thrombocytopenia. One patient had an allergic sensitivity to Nuvarone® and developed a generalized maculopapular erythema with leucopenia each of the three occasions the drug was instituted. Another developed leucopenia (to 3,200 w.b.c.) with no other blood changes and although the drug has been continued three years the leucocyte count has gradually increased to 7,500.